HRP20171468T1 - Obogaćivanje i identificiranje fetalnih stanica u majčinskoj krvi, te ligandi namijenjenu u tu svrhu - Google Patents
Obogaćivanje i identificiranje fetalnih stanica u majčinskoj krvi, te ligandi namijenjenu u tu svrhu Download PDFInfo
- Publication number
- HRP20171468T1 HRP20171468T1 HRP20171468TT HRP20171468T HRP20171468T1 HR P20171468 T1 HRP20171468 T1 HR P20171468T1 HR P20171468T T HRP20171468T T HR P20171468TT HR P20171468 T HRP20171468 T HR P20171468T HR P20171468 T1 HRP20171468 T1 HR P20171468T1
- Authority
- HR
- Croatia
- Prior art keywords
- marker
- cells
- sample
- endothelial
- hybridization probe
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Postupak izdvajanja fetalne stanice u uzorku majčinske krvi, naznačen time što se navedeni postupak sastoji u koracima:
a. osiguravanja uzorka majčinske krvi ili njegove frakcije
b. stavljanja uzorka u kontakt s hibridizacijskom sondom koja sadrži najmanje 10 uzastopnih nukleotida komplementarnih genu koji kodira marker za endotelne stanice ili s ligandom usmjerenim na marker za endotelne stanice, gdje se marker za endotelne stanice bira iz skupine koju čine CD105, CD146, CD141, Vimentin, VCAM, ICAM, VEGFR-1, VEGFR-2, VEGFR-3, ITGA5, ITGB5, CDH11 ili CDH3 i
c. odabira stanica specifičnih za navedeni marker za endotelne stanice, čime se uzorak obogaćuje stanicama s endotelnim fenotipom
d. stavljanja u kontakt stanica odabranih u c) koje pokazuju endotelni fenotip s hibridizacijskom sondom koja sadrži najmanje 10 uzastopnih nukleotida komplementarnih genu koji kodira marker za epiteline stanice ili s ligandom usmjerenim na marker za epiteline stanice, gdje se marker za epiteline stanice bira iz skupine koju čine CK1, CK2, CK3, CK4, CK5, CK6, CK7, CK8, CK9, CK10, CK13, CK14, CK15, CK16, CK17, CK18 ili CK19,
e. detektiranje stanica s endotelnim fenotipom koje se također vežu s markerom za epiteline stanice iz koraka d)
f. izbornog dijagnosticiranja i/ili predviđanja genetskog sadržaja stanica detektiranih u e)
gdje se korake b-e može provesti bilo kojim redoslijedom.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se cilj endotelnog markera nalazi na površini stanice koju treba identificirati.
3. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se cilj epitelnog markera nalazi unutar stanice koju treba identificirati.
4. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koracima
a. osiguravanja uzorka majčinske krvi ili njegove frakcije
b. stavljanja uzorka u kontakt s
i. hibridizacijskom sondom koja sadrži najmanje 10 uzastopnih nukleotida komplementarnih genu koji kodira marker za endotelne stanice ili
ii. ligandom usmjerenim na marker za endotelne stanice
c. odabira stanica koje se vežu s hibridizacijskom sondom ili s ligandom iz prethodnog koraka, čime se uzorak obogaćuje stanicama koje se vežu s hibridizacijskom sondom ili s ligandom iz prethodnog koraka
d. stavljanja u kontakt obogaćenog uzorka s
i. hibridizacijskom sondom koja sadrži najmanje 10 uzastopnih nukleotida komplementarnih genu koji kodira marker za epiteline stanice ili
ii. ligandom usmjerenim na marker za epiteline stanice.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što dodatno uključuje korak identificiranja fetalnih stanica u uzorku.
6. Postupak u skladu s bilo kojim od patentnih zahtjeva 4 i 5, naznačen time što se identificiranje sastoji u detektiranju prisutnosti liganda usmjerenog na marker za epiteline stanice ili hibridizacijske sonde usmjerene na marker za epiteline stanice na ili u fetalnoj stanici.
7. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je uzorak majčinske krvi puna krv.
8. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se stanice u uzorku podvrgne koraku fiksiranja nakon koraka odabira odnosno obogaćivanja.
9. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se stanice u uzorku permeabilizira nakon koraka fiksiranja i prije stavljanja u kontakt s ligandom usmjerenim na marker za epiteline stanice ili hibridizacijskom sondom.
10. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se marker za endotelne stanice bira iz skupine koju čine: CD105, CD146 ili CD141.
11. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je marker za endotelne stanice CD105.
12. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se marker za epiteline stanice bira iz skupine koju čine: CK8, CK18, CK19 ili CK7.
13. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se sastoji u stavljanju u kontakt uzorka s protutijelom M30.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201001018 | 2010-11-09 | ||
| EP11785308.5A EP2638176B1 (en) | 2010-11-09 | 2011-11-09 | Enrichment and identification of fetal cells in maternal blood and ligands for such use |
| PCT/DK2011/050423 WO2012062325A1 (en) | 2010-11-09 | 2011-11-09 | Enrichment and identification of fetal cells in maternal blood and ligands for such use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171468T1 true HRP20171468T1 (hr) | 2017-12-15 |
Family
ID=45001595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171468TT HRP20171468T1 (hr) | 2010-11-09 | 2011-11-09 | Obogaćivanje i identificiranje fetalnih stanica u majčinskoj krvi, te ligandi namijenjenu u tu svrhu |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9429520B2 (hr) |
| EP (1) | EP2638176B1 (hr) |
| JP (2) | JP6068354B2 (hr) |
| KR (2) | KR102057931B1 (hr) |
| CN (1) | CN103261439B (hr) |
| CA (1) | CA2817390C (hr) |
| CY (1) | CY1119526T1 (hr) |
| DK (1) | DK2638176T3 (hr) |
| EA (1) | EA027314B1 (hr) |
| ES (1) | ES2642313T3 (hr) |
| HR (1) | HRP20171468T1 (hr) |
| HU (1) | HUE034937T2 (hr) |
| IL (1) | IL226188A (hr) |
| LT (1) | LT2638176T (hr) |
| PL (1) | PL2638176T3 (hr) |
| PT (1) | PT2638176T (hr) |
| RS (1) | RS56402B1 (hr) |
| SG (2) | SG10201509230VA (hr) |
| SI (1) | SI2638176T1 (hr) |
| SM (1) | SMT201700509T1 (hr) |
| WO (1) | WO2012062325A1 (hr) |
| ZA (1) | ZA201303148B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2642313T3 (es) * | 2010-11-09 | 2017-11-16 | Arcedi Biotech Aps | Enriquecimiento e identificación de células fetales en sangre materna y ligandos para tal uso |
| WO2014067528A1 (en) | 2012-10-29 | 2014-05-08 | Arcedi Biotech Aps | Improved enrichment and detection of rare blood cells |
| AU2015215008B2 (en) * | 2014-02-05 | 2019-11-28 | Fujirebio Diagnostics Ab | Composition and method for detecting malignant neoplastic disease |
| CN106537144A (zh) * | 2014-08-05 | 2017-03-22 | 富士胶片株式会社 | 有核红血球的分选方法 |
| EP3247789A4 (en) * | 2015-01-23 | 2018-09-12 | Unimed Biotech (Shanghai) Co., Ltd. | Microfluidics based fetal cell detection and isolation for non-invasive prenatal testing |
| CN104977284B (zh) * | 2015-07-03 | 2018-05-29 | 石莹 | 一种胎儿有核红细胞的捕获及鉴定方法 |
| CN107475358A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 结直肠癌组织溯源ctc分型鉴定试剂盒 |
| CN107475354A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 前列腺癌组织溯源ctc分型鉴定试剂盒 |
| CN107475353A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 肺癌组织溯源ctc分型鉴定试剂盒 |
| US20180299442A1 (en) * | 2017-04-14 | 2018-10-18 | Jennifer C. Chow | Enrichment and identification of fetal material |
| CN111122520A (zh) * | 2018-10-31 | 2020-05-08 | 四川大学华西第二医院 | 一种胚胎植入检测试剂盒及其应用和使用方法 |
| WO2020158824A1 (ja) * | 2019-01-30 | 2020-08-06 | 大日本印刷株式会社 | 小腸上皮細胞を含む細胞構造物、その製造のための方法、及び、それを保持する基材 |
| SG11202113242QA (en) | 2019-06-07 | 2021-12-30 | Arcedi Biotech Aps | Isolation of fetal cells using facs |
| AU2020315211A1 (en) * | 2019-07-15 | 2022-02-10 | A. Menarini Biomarkers Singapore Pte. Ltd. | Compositions and methods for isolating, detecting, and analyzing fetal cells |
| MX2022015727A (es) | 2020-06-10 | 2023-03-23 | Univ Texas | Metodo para determinar riesgo de parto prematuro. |
| WO2022165084A1 (en) | 2021-01-27 | 2022-08-04 | Biofluidica, Inc. | High efficiency capture of fetal cells from maternal samples |
| WO2023104773A1 (en) * | 2021-12-06 | 2023-06-15 | Arcedi Biotech Aps | Isolation and diagnostics of fetal cells |
| CN115109780B (zh) * | 2022-06-22 | 2024-07-05 | 湖南大学 | 一种特异性识别并结合循环胎儿有核红细胞的核酸适体、互补序列及它们的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641628A (en) | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
| BR9306867A (pt) | 1992-07-17 | 1998-12-08 | Aprogenex Inc | Enriquecimento e identificação de células fetais do sangue materno para a hibridização in situ |
| US5629147A (en) | 1992-07-17 | 1997-05-13 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
| US5714325A (en) * | 1993-09-24 | 1998-02-03 | New England Medical Center Hospitals | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood |
| GB0009179D0 (en) | 2000-04-13 | 2000-05-31 | Imp College Innovations Ltd | Non-invasive prenatal diagnosis |
| WO2001088100A1 (en) * | 2000-05-16 | 2001-11-22 | Kyowa Hakko Kogyo Co., Ltd. | Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof |
| AU2002306768A1 (en) * | 2001-03-20 | 2002-10-03 | Ortho-Clinical Diagnostics, Inc. | Expression profiles and methods of use |
| ES2564312T3 (es) * | 2007-05-01 | 2016-03-21 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Métodos y kits para detectar células fetales en la sangre materna |
| CA2752838A1 (en) | 2008-02-18 | 2009-08-27 | Genetic Technologies Limited | Cell processing and/or enrichment methods |
| EP2634268A3 (en) * | 2009-01-07 | 2013-12-25 | QuantiBact A/S | Enrichment and identification of fetal cells in maternal blood and ligands for such use |
| EP2389455A4 (en) | 2009-01-26 | 2012-12-05 | Verinata Health Inc | METHODS AND COMPOSITIONS FOR IDENTIFYING A FETAL CELL |
| US20120115167A1 (en) * | 2009-04-22 | 2012-05-10 | Clinical Genomics Pty. Ltd. | Method and apparatus for isolating a target bioentity from a biological sample |
| ES2642313T3 (es) * | 2010-11-09 | 2017-11-16 | Arcedi Biotech Aps | Enriquecimiento e identificación de células fetales en sangre materna y ligandos para tal uso |
-
2011
- 2011-11-09 ES ES11785308.5T patent/ES2642313T3/es active Active
- 2011-11-09 PT PT117853085T patent/PT2638176T/pt unknown
- 2011-11-09 LT LTEP11785308.5T patent/LT2638176T/lt unknown
- 2011-11-09 WO PCT/DK2011/050423 patent/WO2012062325A1/en not_active Ceased
- 2011-11-09 SG SG10201509230VA patent/SG10201509230VA/en unknown
- 2011-11-09 US US13/883,455 patent/US9429520B2/en active Active
- 2011-11-09 EP EP11785308.5A patent/EP2638176B1/en active Active
- 2011-11-09 JP JP2013538070A patent/JP6068354B2/ja active Active
- 2011-11-09 CN CN201180056239.5A patent/CN103261439B/zh active Active
- 2011-11-09 CA CA2817390A patent/CA2817390C/en active Active
- 2011-11-09 KR KR1020187009057A patent/KR102057931B1/ko active Active
- 2011-11-09 SG SG2013034756A patent/SG190175A1/en unknown
- 2011-11-09 SM SM20170509T patent/SMT201700509T1/it unknown
- 2011-11-09 SI SI201131305T patent/SI2638176T1/en unknown
- 2011-11-09 DK DK11785308.5T patent/DK2638176T3/da active
- 2011-11-09 KR KR1020137014118A patent/KR20130102612A/ko not_active Ceased
- 2011-11-09 RS RS20170977A patent/RS56402B1/sr unknown
- 2011-11-09 HU HUE11785308A patent/HUE034937T2/en unknown
- 2011-11-09 HR HRP20171468TT patent/HRP20171468T1/hr unknown
- 2011-11-09 PL PL11785308T patent/PL2638176T3/pl unknown
- 2011-11-09 EA EA201390638A patent/EA027314B1/ru unknown
-
2013
- 2013-04-30 ZA ZA2013/03148A patent/ZA201303148B/en unknown
- 2013-05-06 IL IL226188A patent/IL226188A/en active IP Right Grant
-
2016
- 2016-12-22 JP JP2016249311A patent/JP6310540B2/ja active Active
-
2017
- 2017-10-31 CY CY20171101136T patent/CY1119526T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171468T1 (hr) | Obogaćivanje i identificiranje fetalnih stanica u majčinskoj krvi, te ligandi namijenjenu u tu svrhu | |
| Green et al. | Beyond the capture of circulating tumor cells: next‐generation devices and materials | |
| Shen et al. | Specific capture and release of circulating tumor cells using aptamer‐modified nanosubstrates | |
| Millner et al. | Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes | |
| Poudineh et al. | Profiling circulating tumour cells and other biomarkers of invasive cancers | |
| Del Ben et al. | A method for detecting circulating tumor cells based on the measurement of single‐cell metabolism in droplet‐based microfluidics | |
| Ahmed et al. | Isolation, detection, and antigen‐based profiling of circulating tumor cells using a size‐dictated immunocapture chip | |
| Yang et al. | Circulating tumor cells from enumeration to analysis: current challenges and future opportunities | |
| Lu et al. | NanoVelcro Chip for CTC enumeration in prostate cancer patients | |
| Mohamadi et al. | Nanoparticle‐mediated binning and profiling of heterogeneous circulating tumor cell subpopulations | |
| Peng et al. | Conducting polymers for electrochemical DNA sensing | |
| Liu et al. | Research progress on detection techniques for point-of-care testing of foodborne pathogens | |
| Saito et al. | The acceleration of dissolved cobalt's ecological stoichiometry due to biological uptake, remineralization, and scavenging in the Atlantic Ocean | |
| Abalde‐Cela et al. | Multiplexing liquid biopsy with surface‐enhanced Raman scattering spectroscopy | |
| ATE489482T1 (de) | Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon | |
| JP2013503630A5 (hr) | ||
| JP2013532295A5 (hr) | ||
| Gao et al. | Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip | |
| Ghosh | Early detection of cancer: Focus on antibody coated metal and magnetic nanoparticle-based biosensors | |
| JP2015505370A5 (hr) | ||
| Ghosh et al. | Late Quaternary climate variability and vegetation response in Ziro Lake Basin, Eastern Himalaya: a multiproxy approach | |
| Hu et al. | Assessing breast cancer molecular subtypes using extracellular vesicles’ mRNA | |
| JP2018528441A5 (hr) | ||
| CN104458774A (zh) | 一种利用生物内部纳米微粒寻找隐伏矿床的方法 | |
| Zeinali et al. | Profiling heterogeneous circulating tumor cells (CTC) populations in pancreatic cancer using a serial microfluidic CTC carpet chip |